PharmClass

The Ministry of Health’s Drug Advisory Committee has recommended:

• Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
• Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials

  for the management of focal spasticity of the lower limbs associated with stroke in adults who:

  • have a score of 3 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
  • do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
  • are concurrently receiving physiotherapy.

Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.

Funding status

The Ministry of Health’s Drug Advisory Committee has recommended:

• Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
• Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials

  for the management of focal spasticity of the upper limbs associated with stroke in adults who:

  • have a score of 2 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
  • do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
  • are concurrently receiving physiotherapy.

Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.

Funding status

The Ministry of Health’s Drug Advisory Committee has recommended:

• Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
• Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials

for treating adults with blepharospasm or hemifacial spasm.

Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.

Funding status

The Ministry of Health’s Drug Advisory Committee has recommended:

• Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
• Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials

for treating adults with cervical dystonia.

Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.

Funding status

The Ministry of Health’s Drug Advisory Committee has recommended:

• Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials, and
• Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 units and 500 units injection vials

  for treating children, aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who:

  • do not have significant joint contractures, i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle; and
  • are concurrently receiving ongoing supportive therapy, e.g. physiotherapy or occupational therapy.

Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.

Funding status